GO
Loading...

ARIAD Pharmaceuticals Inc

More

  • Arista and Noodles are big market movers Friday, 20 Feb 2015 | 4:59 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Arista Networks Inc., up 51 cents to $68.50. Novo Nordisk, up $2.38 to $47.55.

  • Nasdaq stocks posting largest percentage increases Friday, 20 Feb 2015 | 1:36 PM ET

    Egalet Corp. rose 29.3 percent to $14.50. Sizmek Inc. rose 15.7 percent to $7.87. Discovery Communications Inc. Series B rose 13.7 percent to $35.00.

  • Most active Nasdaq-traded stocks Friday, 20 Feb 2015 | 1:36 PM ET

    Apple Inc. rose. 1 percent to $128.59 with 24,625,600 shares traded. Applied Materials Inc. rose. 9 percent to $25.15 with 14,805,200 shares traded. Ariad Pharmaceuticals Inc. rose 9.3 percent to $7.95 with 13,200,200 shares traded.

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder, as the company struggles with poor sales of its only drug on the market. Ariad's blood cancer drug, Iclusig, has failed to live up to sales expectations after the U.S. Food...

  • Feb 20- Sarissa Capital Management LP kicked off a proxy battle with Ariad Pharmaceuticals Inc on Friday, demanding the retirement of Harvey Berger, the drugmaker's chief executive and principal founder. The hedge fund, Ariad's largest shareholder with a 6.87 percent stake, according to Thomson Reuters data, has been negotiating Berger's exit with some of...

  • Sarissa Capital seeks Ariad Pharma's CEO's ouster Friday, 20 Feb 2015 | 6:52 AM ET

    Feb 20- Sarissa Capital Management LP said it was seeking the retirement of Ariad Pharmaceuticals Inc Chief Executive Harvey Berger and would nominate its founding partner to the drugmaker's board.

  • Ariad reports 4Q loss Thursday, 19 Feb 2015 | 8:42 AM ET

    CAMBRIDGE, Mass. _ Ariad Pharmaceuticals Inc. on Thursday reported a loss of $5.8 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share. Analysts expected $47 million, according to Zacks.

  • How to play the JPMorgan health conference Friday, 9 Jan 2015 | 11:57 AM ET
    A chemist works in the lab of Ariad Pharmaceuticals.

    History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.

  • After-hours buzz: Apple, Cliffs Natural & more Tuesday, 30 Dec 2014 | 5:02 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Tuesday's after-hours buzz: Apple, Cliffs & more

  • Lightning Round: Slam job done on this one Thursday, 13 Nov 2014 | 6:54 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Oct 24- European regulators recommended continued use of Ariad Pharmaceuticals Inc's cancer drug, Iclusig, in its already approved indications to treat certain kinds of leukemia. However, the European Medicines Agency recommended additional warnings in Iclusig's European product information to minimize the risk of vascular events, Ariad said.

  • Oct 24- European regulators recommended continued use of Ariad Pharmaceuticals Inc's cancer drug Iclusig in its already approved indications to treat certain kinds of leukemia. However, the European Medicines Agency recommended additional warnings in Iclusig's European product information to minimize the risk of vascular events, Ariad said on Friday.

  • Oct 2- Ariad Pharmaceuticals Inc said its experimental lung cancer drug was granted "breakthrough therapy" status by the U.S. Food and Drug Administration, sending the company's shares up as much as 13 percent. Ariad said the designation was based on early results that showed the drug continued to fight against lung cancer in patients who did not respond to...

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • Lightning Round: Yahoo!, Taser & more Wednesday, 3 Sep 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • 17 stocks traders are shorting ahead of earnings Monday, 4 Aug 2014 | 3:01 PM ET

    Sapphire glass and biotech companies are bringing out the bears ahead of this week's earnings.

  • Red-letter day for Dow, S&P, but Nasdaq lags Monday, 2 Jun 2014 | 6:19 PM ET
    Traders on the floor of the New York Stock Exchange.

    Industrials and material stocks were among the day's biggest gainers, while the technology sector ended lower, weighed down by big tech.

  • Midday movers: Allergan, Valeant, US Steel & more Monday, 2 Jun 2014 | 12:20 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Take a look at some of Monday's midday movers:

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • Lightning Round: Walter Energy, Gogo & More Wednesday, 5 Feb 2014 | 6:35 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.